Cargando…

Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat‐and‐extend compared with pro re nata in eyes with neovascular age‐related macular degeneration

PURPOSE: To evaluate treatment outcome at 12 months in eyes with neovascular age‐related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti‐VEGF) injections according to either pro re nata (PRN)‐ or treat‐and‐extend (TE)‐regimen in one clinical setting in Sweden. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aurell, Sandra, Sjövall, Kersti, Paul, Anna, Morén, Åsa, Granstam, Elisabet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767032/ https://www.ncbi.nlm.nih.gov/pubmed/30511374 http://dx.doi.org/10.1111/aos.13989

Ejemplares similares

Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen
por: Hujanen, Pekko, et al.
Publicado: (2023)

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol
por: Lin, Tiezhu, et al.
Publicado: (2020)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration
por: Jia, Huixun, et al.
Publicado: (2022)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
por: Victor, Andi Arus, et al.
Publicado: (2022)

Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration
por: Chandra, Shruti, et al.
Publicado: (2020)

ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
por: Nguyen, Vuong, et al.
Publicado: (2021)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
por: Elwes, Flora, et al.
Publicado: (2018)

Two-year outcomes of pro re nata ranibizumab monotherapy for exudative age-related macular degeneration in Japanese patients
por: Yamamoto, Akiko, et al.
Publicado: (2013)

Bacterial keratitis in a Swedish county hospital: management and clinical outcome
por: Aurell, Sandra, et al.
Publicado: (2015)

One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
por: Wang, Fenghua, et al.
Publicado: (2019)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up
por: Javidi, Simon, et al.
Publicado: (2020)

Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life
por: Inoue, Maiko, et al.
Publicado: (2014)

Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)

Real-Life Efficacy of Bevacizumab Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion according to Pro Re Nata or Treat-and-Extend Regimen in Eyes with or without Epiretinal Membrane
por: Hamam, Moustafa, et al.
Publicado: (2022)

Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study
por: Yang, Benjamin Chi-Lan, et al.
Publicado: (2019)

Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy
por: Chen, Yu-Yen, et al.
Publicado: (2019)

Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019)

Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial
por: Yoon, Chang Ki, et al.
Publicado: (2022)

Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
por: Gurung, Rajya L, et al.
Publicado: (2021)

Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD
por: Kamao, Hiroyuki, et al.
Publicado: (2018)

Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis
por: Yin, Xiaobei, et al.
Publicado: (2022)

Histology of neovascular myopic macular degeneration
por: Jonas, Shefali B., et al.
Publicado: (2021)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen
por: Hirata, Yuki, et al.
Publicado: (2022)

Cataract surgery in neovascular AMD: impact on visual acuity and disease activity
por: Tang, Hin Yan, et al.
Publicado: (2023)

Pro Re Nata Use of Psychotropic Medications in Assisted Living
por: Carder, Paula, et al.
Publicado: (2020)

Incidence of Acute Endophthalmitis after Intravitreal Antivascular Endothelial Growth Factor Injection in Age-related Macular Degeneration
por: Seong, Hyo Jin, et al.
Publicado: (2022)

One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2022)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
por: Matsumoto, Hidetaka, et al.
Publicado: (2023)

Real-world experience with pro re nata dosing of intravitreal dexamethasone implant for eyes with refractory diabetic macular edema
por: Rishi, Pukhraj, et al.
Publicado: (2020)

The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen
por: Takamura, Yoshihiro, et al.
Publicado: (2021)

Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients
por: Kim, Kyung Tae, et al.
Publicado: (2021)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Pro Re Nata Prescription and Perception Difference between Doctors and Nurses
por: Oh, Se Hwa, et al.
Publicado: (2014)

Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021)

Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration
por: Vofo, Brice Nguedia, et al.
Publicado: (2022)

Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice
por: Sato, Shinri, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t8s88k1rbf8j7u1l189b1bep3o